ELISA/assay

KRIBIOLISA™ Etanercept ELISA (ENBREL)

KBI1013

1 x 96 wells

490 USD

KRIBIOLISA™ Etanercept ELISA (ENBREL)

ELISA

1 x 96 wells

490 USD

Sensitivity: 2.5ng/ml Sample Type: Serum, Plasma Calibrator Range: 0 - 160ng/ml Enzyme Immunoassay for the quantitative determination of Etanercept in serum, plasma and cell culture supernatant . Etanercept is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor (TNF, a soluble inflammatory cytokine) by acting as a TNF inhibitor. It has U.S. F.D.A. approval to treat rheumatoid arthritis, juvenile rheumatoid arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. TNF-alpha is the "master regulator" of the inflammatory (immune) response in many organ systems. Autoimmune diseases are caused by an overactive immune response. Etanercept has the potential to treat these diseases by inhibiting TNF-alpha. Krishgen PK kits, developed using the innovator drug as calibrator, are used for the quantitation of serum protein drug levels, and can be used for biosimilar and generics research as well. About the kit: - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Ready to use with a standard protocol with break-apart pre-coated wells - Validated as per US FDA guidelines for Bioassays - Optimized for matrix effects to ensure higher sensitivity. - Shelf life: 1 year The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Etanercept are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Etanercept present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Etanercept antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Etanercept in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Human

Etanercept is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor (TNF, a soluble inflammatory cytokine) by acting as a TNF inhibitor. It has U.S. F.D.A. approval to treat rheumatoid arthritis, juvenile rheumatoid arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. TNF-alpha is the "master regulator" of the inflammatory (immune) response in many organ systems. Autoimmune diseases are caused by an overactive immune response. Etanercept has the potential to treat these diseases by inhibiting TNF-alpha.

This ELISA kit comes with a pre-coated plate, concentrated or lyophilized standards, wash solution, subtrate, stop solution and all the required diluents. For the exact contents of the kit, please refer to the datasheet / IFU.

2-8 Deg C

2.5 ng/ml - 160 ng/ml

2.5ng/ml

The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Etanercept are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Etanercept present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Etanercept antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Etanercept in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Etanercept

CE IVD

2-8 degrees C